Bioporto A/S logo

BIOPOR - Bioporto A/S News Story

DKK4.1 -0.1  -3.2%

Last Trade - 07/05/21

Sector
Industrials
Size
Small Cap
Market Cap £128.4m
Enterprise Value £117.0m
Revenue £2.72m
Position in Universe 835th / 1838

BRIEF-Bioporto Says Initiates Pivotal Clinical Study With The NGAL Test For Children  

Tue 2nd October, 2018 6:01pm
Oct 2 (Reuters) - Bioporto A/S  BIOPOR.CO :
    * BIOPORTO INITIATES PIVOTAL CLINICAL STUDY WITH THE NGAL
TEST™
FOR CHILDREN   
    * STUDY WILL FORM BASIS FOR AN ADDITIONAL APPLICATION FOR
U.S. FDA
REGULATORY CLEARANCE OF NGAL TEST
    * SAYS EXPECTS TO SUBMIT AN APPLICATION TO FDA IN FIRST HALF
OF
2019

Source text for Eikon:  ID:nGNE24NZgP 
Further company coverage:  BIOPOR.CO 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.